Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2 alterations across solid tumors: implications for comprehensive testing.

The oncologist - 1 Sept 2025

Ismail Ahmed, Jani Chimay, Jahan Nusrat, Midhun Malla, Basu Arnab, Gupta Garima, El-Rayes Bassel, Bae Sejong, Mattox Tyler, Hawkins Cyntanna, Arend Rebecca C, Akce Mehmet, Boumber Yanis, Desai Aakash

Abstract excerpt

PURPOSE: ERBB2 (HER2) alterations (eg, overexpression, amplification, and mutations) are known to drive tumor progression. These changes, particularly in non-breast and gastric/gastroesophageal cancers, remain poorly characterized. With pan-tumor approval of HER2-targeted therapies like Trastuzumab deruxetecan (T-DXd), understanding ERBB2 alterations across diverse cancers is crucial. METHODS: HER2 analysis was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Cells and Metastasis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HER2/EGFR in Cancer Research

Source

Open in PubMed Open full text

Identifiers

PMID: 40828885
DOI: 10.1093/oncolo/oyaf258
PMCID: PMC12448436

Genes

ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2 alterations across solid tumors: implications for comprehensive testing.PMID 40828885Read ↗

Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.Semantic proximity Read ↗

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.Semantic proximity Read ↗

ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers.Semantic proximity Read ↗

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse MalignanciesSemantic proximity Read ↗

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read ↗

Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors.Semantic proximity Read ↗

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.Semantic proximity Read ↗

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.Semantic proximity Read ↗

International Harmonization of Provisional Diagnostic Criteria for ERBB2-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing PanelSemantic proximity Read ↗

Tumor Mutational Landscape and Its Correlation With Histopathological Characteristics in Breast Cancer.Semantic proximity Read ↗

"Beyond HER2 overexpression: somatic alterations in HER2 and PI3K genes in HER2-high and HER2-low/TNBC breast cancer.Semantic proximity Read ↗

Tumor Mutational Landscape and Its Correlation with Histopathological Characteristics in Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.